CureVac (NASDAQ:CVAC) recently reported disappointing efficacy data from the phase 3 trial of its coronavirus vaccine candidate. The company expects more data and then will decide on what to do next. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss what a potential win means for CureVac — and how a potential loss may help today’s vaccine leaders.
Olivia Zitkus: Is CureVac still looming large as a potential player in the general vaccine space? Has the company signed any other major purchase agreements that investors are still holding onto for some hope here?
Adria Cimino: As a matter of fact, they have. It could be a big player in Europe. They signed a deal in Europe for as many as 405 million doses. That includes the option for more doses, so that will be a total of at maximum 405 million doses. They can be a pretty good provider in Europe. We’ll have to see if that’s going to go through or not depending on what happens with the final analysis. Now, if this falls through, this might be positive news for Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) because chances are Europe is looking for more doses. Europe has struggled with supply issues and got behind in vaccinations and everything. It’s very possible that if the CureVac deal falls through, they’re going to be looking for more doses elsewhere. Then, of course, we have Pfizer and Moderna ready to provide them. It very well could be good news for Pfizer and Moderna or maybe even Novavax down the road.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Need Your Help Today. Your $1 can change life.